-
公开(公告)号:US09938222B2
公开(公告)日:2018-04-10
申请号:US15509214
申请日:2015-09-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter T. W. Cheng , Ying Wang , Sutjano Jusuf , Shiwei Tao , Hao Zhang , Shung C. Wu , Jeffrey A. Robl
IPC: C07C62/34 , C07C59/64 , C07D307/79 , C07D277/30 , C07D213/55 , C07D231/12 , C07D213/65
CPC classification number: C07C62/34 , A61K31/192 , A61K31/343 , A61K31/415 , A61K31/426 , A61K31/44 , A61K31/4418 , C07C59/64 , C07C2601/02 , C07D207/323 , C07D213/55 , C07D213/65 , C07D231/12 , C07D277/30 , C07D277/593 , C07D307/79 , C07D307/82
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
-
公开(公告)号:US20170247311A1
公开(公告)日:2017-08-31
申请号:US15509225
申请日:2015-09-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Ying Wang , Peter T.W. Cheng , Shung C. Wu
IPC: C07C59/72 , A61K31/192 , C07D213/64 , A61K31/4418 , C07D213/70 , C07D271/06 , A61K31/4245 , C07D213/65 , C07D277/24 , A61K31/426 , C07D307/79 , A61K31/343 , C07D213/68 , C07D237/14 , A61K31/50 , C07D309/12 , A61K31/351 , A61K45/06
CPC classification number: C07C59/72 , A61K31/192 , A61K31/343 , A61K31/351 , A61K31/4245 , A61K31/426 , A61K31/4418 , A61K31/50 , A61K45/06 , C07C59/90 , C07C62/34 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2602/50 , C07C2603/50 , C07D213/64 , C07D213/643 , C07D213/65 , C07D213/68 , C07D213/70 , C07D237/14 , C07D271/06 , C07D277/24 , C07D307/79 , C07D309/12
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
-
公开(公告)号:US09518000B2
公开(公告)日:2016-12-13
申请号:US14774289
申请日:2014-03-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter T. W. Cheng , Ying Wang , Shung C. Wu , Hao Zhang
IPC: C07D205/04 , C07D231/12 , C07D239/38 , C07D271/06 , C07D307/79 , C07D333/16 , C07D333/28 , C07D333/56 , A61K45/06 , A61K31/343 , A61K31/381 , A61K31/397 , A61K31/415 , A61K31/4245 , A61K31/505 , C07C59/13 , C07C69/675 , C07C69/708 , C07C69/732 , C07C69/734 , C07C69/736 , C07C69/757 , C07C69/76 , C07C43/192 , C07C43/196 , C07C47/277 , C07C59/72 , C07C62/34 , C07C311/51 , C07C235/26 , C07C237/22 , A61K31/192 , C07C59/215 , C07C205/34 , C07C323/19
CPC classification number: C07C59/13 , A61K31/192 , A61K31/343 , A61K31/381 , A61K31/397 , A61K31/415 , A61K31/4245 , A61K31/505 , A61K45/06 , C07C43/192 , C07C43/196 , C07C47/277 , C07C59/215 , C07C59/72 , C07C62/34 , C07C69/675 , C07C69/708 , C07C69/732 , C07C69/734 , C07C69/736 , C07C69/757 , C07C69/76 , C07C205/34 , C07C235/26 , C07C237/22 , C07C311/51 , C07C323/19 , C07C2601/02 , C07C2602/08 , C07C2602/42 , C07D205/04 , C07D231/12 , C07D239/38 , C07D271/06 , C07D307/79 , C07D333/16 , C07D333/28 , C07D333/56
Abstract: The present invention provides compounds of Formula (I): (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
-
公开(公告)号:US20230339884A1
公开(公告)日:2023-10-26
申请号:US18321092
申请日:2023-05-22
Applicant: Bristol-Myers Squibb Company
Inventor: Yan Shi , Peter Tai Wah Cheng , Ying Wang , Jun Shi , Shiwei Tao , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Hao Zhang , James R. Corte
IPC: C07D403/04 , C07D249/06 , A61P35/00 , C07C249/06 , C07D401/04 , C07C403/04
CPC classification number: C07D401/04 , A61P35/00 , C07C249/06 , C07C403/04 , C07D249/06 , C07D403/04 , A61P1/16
Abstract: The present invention provides compounds of Formula (I):
or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.-
公开(公告)号:US11384067B2
公开(公告)日:2022-07-12
申请号:US16954310
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter Tai Wah Cheng , Ying Wang
IPC: C07D403/04 , C07D401/04
Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; Q2 is N or NR5a; one of Q1 and Q3 is CR5, and the other is N or NR5a; and the dashed circle denotes optional bonds forming an aromatic ring; Y1 is O or NR3; Y2 is —CO—, —SO2—, or —S(O(NH)—; Y3 is O or NR4a; provided that (1) Y1 and Y3 are not both O, and (2) when Y2 is C(O), Y1 is not O; L is a covalent bond or C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 and R4a are independently hydrogen, C1-6 alkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R4 is C1-10 alkyl, C1-10 haloalkyi, C1-10 deuterated alkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)—(C3-8 cycloalkyl), —(C1-6 alkylene)—(6 to 10-membered aryl), —(C1-6 alkylene)—(3 to 8-membered heterocyclyl), or —(C1-6 alkylene)—(5 to 6-membered heteroaryl); wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R; or alternatively, R3 and R4, taken together with the N and 0 atoms which they are attached, form a 4 to 9-membered heterocyclic ring moiety which is substituted with 0 to 3 R8; or alternatively, (R3 and R5a) or (R3 and R5), taken together with the atoms to which they are attached to, form a 5 to 8-membered heterocyclic ring moiety which is substituted with 0 to 3 R8; R5a is hydrogen, C1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R5 and R6 are each independently hydrogen, halo, cyano, hydroxyl, amino, alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R7 is halo, oxo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R8 are each independently deuterium, halo, hydroxyl, amino, cyano, C1-6 alkyl, C1-6 deuterated alkyl, C2-6 alkenyl, C2-6 alkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl; or alternatively, two R8, taken together with the atom(s) to which they are attached, form a 3 to 6-membered carbocyclic ring or a 3 to 6-membered heterocyclic ring each of which is independently substituted with 0 to 3 R12; R9 is selected from —CN, —C(O)OR10, —C(O)NR11aR11b—, —CO—NH—CO—Re, —CO—NH—SO2—Re, —CO—NH—SO—Re, —SO2—OH, —SO2—NH—CO—Re, —P(O)(OH)2, tetrazol-5-yl, —CH2—CO—NH—CO—Re, —CH2—CO—NH—SO2—Re, —CH2—CO—NH—SO—Re, —CH2—SO2—OH, —CH2—SO2—NH—CO—Re, —CH2—P(O)(OH)2, tetrazol-5-ylmethylene; Re is C1-6 alkyl, C3-6 cycloalkyl, haloalkyl, hydroxyalkyi, aminoalkyi, alkoxyalkyi, or haloalkoxyalkyi; R10 is hydrogen or C1-10 alkyl; and R11a and R11b are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, or haloalkoxy; and R12 is halo, cyano, hydroxyl, amino, C1-6 alkyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US11319315B2
公开(公告)日:2022-05-03
申请号:US16772842
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter Tai Wah Cheng , Ying Wang , Jun Li , Tianan Fang , James R. Corte , Jun Shi , Hao Zhang , Lawrence J. Kennedy , Shiwei Tao
IPC: C07D401/14 , C07D403/14 , C07D417/14 , C07D413/14
Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US11312706B2
公开(公告)日:2022-04-26
申请号:US16954325
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Ying Wang , Peter Tai Wah Cheng , Jun Li , Steven J. Walker
IPC: C07D401/14 , C07D403/14 , C07D401/04
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US20210230143A1
公开(公告)日:2021-07-29
申请号:US16772825
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Ying Wang , Peter Tai Wah Cheng , Jun Shi , Shiwei Tao , James R. Corte , Tianan Fang , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Sutjano Jusuf
IPC: C07D401/14 , C07D409/14 , C07D403/14 , C07D401/12 , C07D405/14 , C07D491/052
Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US20200317656A1
公开(公告)日:2020-10-08
申请号:US16954552
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: YAN SHI , Ying Wang , Peter Tai Wah Cheng
IPC: C07D413/14 , C07D413/12
Abstract: The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
公开(公告)号:US10662172B2
公开(公告)日:2020-05-26
申请号:US16223169
申请日:2018-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Yan Shi , Peter Tai Wah Cheng , Ying Wang , Jun Shi , Shiwei Tao , Jun Li , Lawrence J. Kennedy , Robert F. Kaltenbach, III , Hao Zhang , James R. Corte
IPC: C07D401/04 , C07D403/04 , C07D249/06 , A61P35/00 , A61P1/16 , A61P19/10 , A61P13/12 , A61P11/00 , C07C403/04 , C07C249/06
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
-
-
-
-
-
-
-
-
-